Student Research Committee, Infertility Research Center, Laparoscopy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran,
Arch Gynecol Obstet. 2013 Dec;288(6):1301-8. doi: 10.1007/s00404-013-2895-8. Epub 2013 May 28.
To assess the effects of levamisole on experimental endometriosis in rats through the histopathology of the implants, the blood leukocyte and lymphocyte counts and the concentrations of interleukin-6, vascular endothelial growth factor-A and tumor necrosis factor-alpha in the peritoneal environment at the three healthy, endometriotic and post-treatment milestones.
Twenty-two 8-week-old Sprague-Dawley rats with normal estrus cycles were recruited in a prospective, parallel-group, placebo-controlled, double-blind, stratified-randomized animal trial with the equal allocation ratio of 1:1 challenging the efficacy of levamisole. Endometriosis was induced. After 6 weeks, laparotomy was performed to randomly excise one implant for histopathology assessment. Based on the results, they were stratified randomized and allocated (by software) to two groups of nine: levamisole (5 mg/rat/day) or placebo. After 6 weeks, necropsy was done. Two days before each laparotomy, blood samples and during the procedure, peritoneal wash were collected for ELISA.
Seven rats showed success in treatment in the levamisole group, while three did in the other group. The histopathology results descriptively revealed a drop in the levamisole group, which was not meaningful statistically (0.66 ± 1.32 vs. 2.00 ± 1.50, p = 0.065). The comparisons of the post-treatment leukocytes and lymphocytes in the groups showed significant differences (11088.88 ± 5869.50 vs. 4677.77 ± 3476.98, p = 0.008, and 8588.88 ± 5721.32 vs. 3511.11 ± 2835.24, p = 0.014, respectively). The results of the cytokines were mostly, but not completely, in favor of the efficacy of levamisole.
This study indicates a possible successful role for levamisole in the treatment of experimental endometriosis. Further studies to assess the effects of high dose levamisole on endometriosis are recommended.
通过评估植入物的组织病理学、血白细胞和淋巴细胞计数以及腹腔环境中白细胞介素 6、血管内皮生长因子-A 和肿瘤坏死因子-α的浓度，评估左旋咪唑对大鼠实验性子宫内膜异位症的影响。
在一项前瞻性、平行组、安慰剂对照、双盲、分层随机动物试验中，招募了 22 只 8 周龄、具有正常发情周期的 Sprague-Dawley 大鼠，采用 1:1 比例的等效分配比例，以验证左旋咪唑的疗效。诱导子宫内膜异位症。6 周后，行剖腹术随机切除一个植入物进行组织病理学评估。根据结果，对其进行分层随机分组，分为两组（每组 9 只）：左旋咪唑（5mg/大鼠/天）或安慰剂。6 周后行尸检。在每次剖腹术前 2 天及手术过程中采集血样和腹腔灌洗液，进行 ELISA 检测。
左旋咪唑组 7 只大鼠治疗成功，另一组 3 只。组织病理学结果描述性地显示左旋咪唑组有所下降，但统计学上无意义（0.66±1.32 与 2.00±1.50，p=0.065）。组间治疗后白细胞和淋巴细胞比较差异有统计学意义（11088.88±5869.50 与 4677.77±3476.98，p=0.008，8588.88±5721.32 与 3511.11±2835.24，p=0.014）。细胞因子的结果大多但不完全支持左旋咪唑的疗效。
本研究表明左旋咪唑在治疗实验性子宫内膜异位症中可能有一定的作用。建议进一步研究评估高剂量左旋咪唑对子宫内膜异位症的影响。
